BILLERICA, Mass., Dec. 23, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) announced today that Brent Alldredge, Chief Legal Officer and Corporate Secretary, has notified the Company that he will be departing the Company on January 16, 2022 to become the General Counsel at Bruker Corporation, a global, publicly traded developer, manufacturer, and distributor of scientific instruments and analytical and diagnostic solutions.
As a result, the Company’s Board of Directors has begun a search to appoint a successor to Mr. Alldredge, with a further announcement to be made in due course. Mr. Alldredge has agreed to work with the Company as an advisor to help achieve a smooth transition.
“Since joining Conformis in 2019, Brent has been a trusted advisor and valued member of the executive management team. His new position at a multi-billion dollar, large market cap company is an indication of his experience and capabilities,” said Mark Augusti, President and Chief Executive Officer. “On behalf of the Company and the Board, I would like to thank Brent for his hard work and significant contributions.”
“It has been a privilege,” said Mr. Alldredge, “to work with a strong management team that is dedicated to maximizing the potential of Conformis’ unique technologies and service offerings to benefit patients, surgeons, and shareholders. Considering the Company’s state-of-the-art technology and the ongoing evolution of its products and service offerings, I am confident that Conformis is well positioned for future success.”
About Conformis, Inc.
Conformis is a medical technology company that uses its proprietary iFit
®
Image-to-Implant
®
technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient’s unique anatomy. Conformis also offers Identity Imprint™, a new line of total knee replacement products that utilizes a proprietary algorithm to select the implant size that most closely meets the geometric and anatomic requirements of the patient’s knee. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.
For more information, visit
www.conformis.com
. To receive future releases in e-mail alerts, sign up at
ir.conformis.com
.
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release about our future expectations, plans and prospects, the anticipated timing of our product launches, and our financial position and results, total revenue, product revenue, gross margin, operations and growth, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these terms or other and similar expressions are intended to identify forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties; risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations, and the other risks and uncertainties described in the “Risk Factors” sections of our public filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.
Investor Contact
[email protected]
(781) 374-5598
Source: Conformis, Inc.
